{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:12:11Z","timestamp":1788315131147,"version":"build-2803163510"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2022JH2\/101500012"],"award-info":[{"award-number":["2022JH2\/101500012"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Ixekizumab, a monoclonal antibody targeting IL-17A, is approved for psoriasis (PsO) and psoriatic arthritis (PsA). While clinical trials demonstrate its efficacy, real-world safety insights remain critical due to limitations in detecting rare or delayed adverse events (AEs).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This study analyzed 28,889 ixekizumab-associated AE reports from the first quarter of 2016 to the third quarter of 2024 in the FDA Adverse Event Reporting System (FAERS) using disproportionality methods (ROR, PRR, MGPS, BCPNN) and Weibull distribution modeling. Subgroup and sensitivity analyses were conducted to evaluate demographic variations and confounding factors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Common AEs included injection site reaction, fungal infections, and upper respiratory infections. Novel signals included myocardial infarction, herpes zoster, and inflammatory bowel disease. Subgroup analyses revealed male-predominant cardiac risks and age-dependent patterns (pediatric injection reactions vs elderly herpes zoster). Median time-to-onset was 56 days (IQR:12\u2013205), with early risk escalation (Weibull \u03b2\u2009=\u20090.60).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This FAERS analysis confirms ixekizumab\u2019s established safety profile while identifying critical demographic-specific and delayed-onset signals. Continuous pharmacovigilance is warranted to optimize risk management, particularly for cardiovascular monitoring in high-risk males and antiviral prophylaxis in elderly patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0323973","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:55:51Z","timestamp":1748022951000},"page":"e0323973","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3209-7184","authenticated-orcid":true,"given":"Yuzhe","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-917X","authenticated-orcid":true,"given":"Jun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"3","key":"pone.0323973.ref001","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(24)00268-6","article-title":"Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease","volume":"7","author":"F Ciccia","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"pone.0323973.ref002","first-page":"176298","article-title":"Psoriatic arthritis: an update","author":"P Lloyd","year":"2012","journal-title":"Arthritis"},{"issue":"3","key":"pone.0323973.ref003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for Psoriasis","volume":"42","author":"AM Wride","year":"2024","journal-title":"Dermatol Clin"},{"issue":"9993","key":"pone.0323973.ref004","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"CEM Griffiths","year":"2015","journal-title":"Lancet"},{"key":"pone.0323973.ref005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"L Liu","year":"2016","journal-title":"J Inflamm Res"},{"issue":"4","key":"pone.0323973.ref006","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"A Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"pone.0323973.ref007","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations","volume":"34","author":"A Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"pone.0323973.ref008","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"8","key":"pone.0323973.ref009","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"KJ Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0323973.ref010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"pone.0323973.ref011","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"SA Rivkees","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pone.0323973.ref012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pone.0323973.ref013","doi-asserted-by":"crossref","first-page":"2160196","DOI":"10.1080\/09546634.2022.2160196","article-title":"Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016-2021","volume":"34","author":"A Reich","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"pone.0323973.ref014","doi-asserted-by":"crossref","first-page":"113474","DOI":"10.1016\/j.intimp.2024.113474","article-title":"Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study","volume":"143","author":"Z Zhao","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"pone.0323973.ref015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-024-03030-5","article-title":"Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab","volume":"42","author":"X Gao","year":"2025","journal-title":"Adv Ther"},{"issue":"9","key":"pone.0323973.ref016","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14740338.2024.2392007","article-title":"Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis","volume":"23","author":"T Battista","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"pone.0323973.ref017","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s12325-024-02812-1","article-title":"Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab","volume":"41","author":"S Chabra","year":"2024","journal-title":"Adv Ther"},{"issue":"6","key":"pone.0323973.ref018","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","article-title":"Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials","volume":"39","author":"S Chabra","year":"2022","journal-title":"Adv Ther"},{"issue":"7","key":"pone.0323973.ref019","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/1346-8138.17245","article-title":"Systemic therapy for psoriasis and the risk of cutaneous infections","volume":"51","author":"Y Higashi","year":"2024","journal-title":"J Dermatol"},{"key":"pone.0323973.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2412221","article-title":"Infection and infestation-related adverse events of biologics in psoriasis: insights from the Food and Drug Administration Adverse Event Reporting System (FAERS)","author":"R Fang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"pone.0323973.ref021","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/14740338.2024.2399092","article-title":"Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies","volume":"23","author":"S Schwartzman","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0323973.ref022","doi-asserted-by":"crossref","first-page":"1353893","DOI":"10.3389\/fmed.2024.1353893","article-title":"Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials","volume":"11","author":"Y Zhang","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"pone.0323973.ref023","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"A Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"pone.0323973.ref024","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s13555-024-01323-9","article-title":"Long-term safety of ixekizumab treatment in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post hoc analysis of cerebro-cardiovascular events","volume":"15","author":"M Lebwohl","year":"2025","journal-title":"Dermatol Ther"},{"issue":"25","key":"pone.0323973.ref025","first-page":"524","article-title":"Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: a retrospective cohort study","author":"WJ Song","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"pone.0323973.ref026","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jad.2024.08.077","article-title":"Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review","volume":"365","author":"M Wang","year":"2024","journal-title":"J Affect Disord"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:56:01Z","timestamp":1748022961000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323973"}},"subtitle":[],"editor":[{"given":"Beatrice","family":"Nardone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323973","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}